Therma Bright Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Therma Bright şirketinin toplam hissedar öz sermayesi CA$1.5M ve toplam borcu CA$40.0K olup, bu da borç-öz sermaye oranını 2.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$4.1M ve CA$2.6M dir.

Anahtar bilgiler

2.6%

Borç/özkaynak oranı

CA$40.00k

Borç

Faiz karşılama oranı	n/a
Nakit	CA$99.00
Eşitlik	CA$1.51m
Toplam yükümlülükler	CA$2.62m
Toplam varlıklar	CA$4.13m

Son finansal sağlık güncellemeleri

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Nov 02

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Jul 04

Recent updates

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Nov 02

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Jul 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: THRM 'nin kısa vadeli varlıkları ( CA$282.9K ) kısa vadeli yükümlülüklerini ( CA$2.6M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: THRM şirketinin kısa vadeli varlıkları ( CA$282.9K ) uzun vadeli yükümlülüklerini ( CA$2.7K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: THRM 'nin net borç/öz sermaye oranı ( 2.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: THRM şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan THRM mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: THRM kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 29.3 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Therma Bright Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Recent updates

Therma Bright Inc. announced that it expects to receive CAD 3 million in funding

Therma Bright Inc. announced that it expects to receive CAD 0.4045 million in funding

Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2023)

Therma Bright Inc. announced that it has received CAD 1 million in funding

New major risk - Shareholder dilution

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2023)

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Dec 18, 2023

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2022)

Therma Bright Inc. and Inretio Inc. Announces Successful Completion of Good Laboratory Practice Study for Its Breakthrough Preva™? Mechanical Thrombectomy Device

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2022)

Full year 2022 earnings released: CA$0.026 loss per share (vs CA$0.043 loss in FY 2021)

Insufficient new directors

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Therma Bright Inc. Provides Update on FDA EUA Review Process

Therma Bright Inc. Provides Updates on Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Third quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.011 loss in 3Q 2021)

Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)

Therma Bright Inc. Provides Update on FDA EUA Application Process for Acuvid(TM) Covid-19 Rapid Antigen Saliva Test

Therma Bright to Submit Application to Health Canada for Approval of its AcuVid COVID-19 Rapid Antigen Saliva Test

Therma Bright Inc., Annual General Meeting, Jun 17, 2022

Second quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.008 loss in 2Q 2021)

Therma Bright Inc. announced that it has received CAD 6 million in funding

Therma Bright Inc. announced that it expects to receive CAD 6 million in funding

Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements

Therma Bright Inc. Completes U.S. Clinical Performance Study Subject Recruitment

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Therma Bright Inc. to Test AcuVidTM on the Highly Contagious COVID-19 Delta Variant; Completes Brazilian Clinical Study for Final FDA EUA Submission

Therma Bright Inc. Provides an Update on the Exceptional Performance of Its AcuVidTM COVID-19 Rapid Antigen Saliva Test's Brazilian Clinical Study

Therma Bright Inc. Provides Update on its Brazilian Clinical Study of its Innovative 15- Minute COVID-19 Antigen Saliva Test

Therma Bright Inc. Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

Therma Bright Inc. Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid (TM) Covid-19 Rapid Saliva- Based Antigen Test

Therma Bright Enters into Clinical Trial Agreement for Its Acuvid(Tm) Covid-19 Rapid Saliva-Based Antigen Test

Independent Director recently sold CA$255k worth of stock

Therma Bright Inc. Reports Improved Accuracy for Covid-19 Rapid Saliva Antigen Test, CoviSafe, and Prepares for Prospective Studies

Therma Bright Inc. Appoints Ian Levine to the Advisory Board

New 90-day high: CA$0.35

First quarter 2021 earnings released: CA$0.018 loss per share

Chairman exercised options to buy CA$248k worth of stock.

New 90-day high: CA$0.28

Full year 2020 earnings released: CA$0.004 loss per share

Therma Bright Inc. (TSXV:THRM) completed the acquisition of assets of Saringer Life Science Technologies Inc. for CAD 0.43 million.

Therma Bright Inc. announced that it has received CAD 1.25 million in funding

New 90-day high - CA$0.30

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin